|
1
|
Peters S, Adjei AA, Gridelli C, Reck M,
Kerr K and Felip E; ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23(Suppl 7): vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
The Surveillance Epidemiology, and End
Results (SEER) Program of the National Cancer Institute: SEER
Cancer Statistics Review, 1975–2011. National Cancer Institute;
Bethesda, MD: 2011
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beckles MA, Spiro SG, Colice GL and Rudd
RM: Initial evaluation of the patient with lung cancer: Symptoms,
signs, laboratory tests, and paraneoplastic syndromes. Chest.
123(Suppl 1): 97S–104S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Schil PE, Balduyck B, De Waele M,
Hendriks JM, Hertoghs M and Lauwers P: Surgical treatment of
early-stage non-small-cell lung cancer. EJC Suppl. 11:110–122.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heide J, Hinkelbein W, Schmittel A and
Kaiser D: Controversies in the Treatment of Lung Cancer. Karger
Medical and Scientific Publishers; Basel: 2010
|
|
8
|
Martini N, Bains MS, Burt ME, Zakowski MF,
McCormack P, Rusch VW and Ginsberg RJ: Incidence of local
recurrence and second primary tumors in resected stage I lung
cancer. J Thorac Cardiovasc Surg. 109:120–129. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mountain CF: Revisions in the
international system for staging lung cancer. Chest. 111:1710–1717.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brock MV, Hooker CM, Ota-Machida E, Han Y,
Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G,
et al: DNA methylation markers and early recurrence in stage I lung
cancer. N Engl J Med. 358:1118–1128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kinch MS, Moore MB and Harpole DH Jr:
Predictive value of the EphA2 receptor tyrosine kinase in lung
cancer recurrence and survival. Clin Cancer Res. 9:613–618.
2003.PubMed/NCBI
|
|
12
|
McFarlane C, McFarlane S, Paul I, Arthur
K, Scheaff M, Kerr K, Stevenson M, Fennell DA and Johnston JA: The
deubiquitinating enzyme USP17 is associated with non-small cell
lung cancer (NSCLC) recurrence and metastasis. Oncotarget.
4:1836–1843. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mio F, Chiba K, Hirose Y, Kawaguchi Y,
Mikami Y, Oya T, Mori M, Kamata M, Matsumoto M, Ozaki K, et al: A
functional polymorphism in COL11A1, which encodes the alpha 1 chain
of type XI collagen, is associated with susceptibility to lumbar
disc herniation. Am J Hum Genet. 81:1271–1277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prockop DJ, Kivirikko KI, Tuderman L and
Guzman NA: The biosynthesis of collagen and its disorders (first of
two parts). N Engl J Med. 301:13–23. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nimni M and Harkness R: Molecular
structures and functions of collagen. Collagen. 1:1–77. 1988.
|
|
16
|
Li Y, Lacerda DA, Warman ML, Beier DR,
Yoshioka H, Ninomiya Y, Oxford JT, Morris NP, Andrikopoulos K,
Ramirez F, et al: A fibrillar collagen gene, Col11a1, is essential
for skeletal morphogenesis. Cell. 80:423–430. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Donoso LA, Edwards AO, Frost AT, Ritter R
III, Ahmad N, Vrabec T, Rogers J, Meyer D and Parma S: Clinical
variability of Stickler syndrome: Role of exon 2 of the collagen
COL2A1 gene. Surv Ophthalmol. 48:191–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Annunen S, Körkkö J, Czarny M, Warman ML,
Brunner HG, Kääriäinen H, Mulliken JB, Tranebjaerg L, Brooks DG,
Cox GF, et al: Splicing mutations of 54-bp exons in the COL11A1
gene cause Marshall syndrome, but other mutations cause overlapping
Marshall/Stickler phenotypes. Am J Hum Genet. 65:974–983. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu YH, Chang TH, Huang YF, Huang HD and
Chou CY: COL11A1 promotes tumor progression and predicts poor
clinical outcome in ovarian cancer. Oncogene. 33:3432–3440. 2014.
View Article : Google Scholar
|
|
20
|
Sok JC, Lee JA, Dasari S, Joyce S,
Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis
JR, et al: Collagen type XI α1 facilitates head and neck squamous
cell cancer growth and invasion. Br J Cancer. 109:3049–3056. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu YH, Chang TH, Huang YF, Chen CC and
Chou CY: COL11A1 confers chemoresistance on ovarian cancer cells
through the activation of Akt/c/EBPβ pathway and PDK1
stabilization. Oncotarget. 6:23748–23763. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chong IW, Chang MY, Chang HC, Yu YP, Sheu
CC, Tsai JR, Hung JY, Chou SH, Tsai MS, Hwang JJ, et al: Great
potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1
markers for diagnosis of patients with non-small cell lung cancer.
Oncol Rep. 16:981–988. 2006.PubMed/NCBI
|
|
23
|
Fischer H, Stenling R, Rubio C and
Lindblom A: Colorectal carcinogenesis is associated with stromal
expression of COL11A1 and COL5A2. Carcinogenesis. 22:875–878. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanoue LT: Staging of non-small cell lung
cancer. Semin Respir Crit Care Med. 29:248–260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
D'Amico TA, Aloia TA, Moore MB, Conlon DH,
Herndon JE II, Kinch MS and Harpole DH Jr: Predicting the sites of
metastases from lung cancer using molecular biologic markers. Ann
Thorac Surg. 72:1144–1148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mountain CF: The international system for
staging lung cancer. Semin Surg Oncol. 18:106–115. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taylor MD, Nagji AS, Bhamidipati CM,
Theodosakis N, Kozower BD, Lau CL and Jones DR: Tumor recurrence
after complete resection for non-small cell lung cancer. Ann Thorac
Surg. 93:1813–1821. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang KK, Liu N, Radulovich N, Wigle DA,
Johnston MR, Shepherd FA, Minden MD and Tsao MS: Novel candidate
tumor marker genes for lung adenocarcinoma. Oncogene. 21:7598–7604.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bignotti E, Tassi RA, Calza S, Ravaggi A,
Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S and
Santin AD: Gene expression profile of ovarian serous papillary
carcinomas: Identification of metastasis-associated genes. Am J
Obstet Gynecol. 196:245.e1–e11. 2007. View Article : Google Scholar
|
|
30
|
Ellsworth RE, Seebach J, Field LA, Heckman
C, Kane J, Hooke JA, Love B and Shriver CD: A gene expression
signature that defines breast cancer metastases. Clin Exp
Metastasis. 26:205–213. 2009. View Article : Google Scholar
|
|
31
|
Miyazono K, Suzuki H and Imamura T:
Regulation of TGF-β signaling and its roles in progression of
tumors. Cancer Sci. 94:230–234. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akhurst RJ and Derynck R: TGF-β signaling
in cancer - a double-edged sword. Trends Cell Biol. 11:S44–S51.
2001.PubMed/NCBI
|
|
33
|
Jeon HS and Jen J: TGF-beta signaling and
the role of inhibitory Smads in non-small cell lung cancer. J
Thorac Oncol. 5:417–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li W, Liu Z, Zhao C and Zhai L: Binding of
MMP-9-degraded fibronectin to β6 integrin promotes invasion via the
FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast
cancer. Oncol Rep. 34:1345–1352. 2015.PubMed/NCBI
|
|
35
|
Chen X, Wang H, Liao HJ, Hu W, Gewin L,
Mernaugh G, Zhang S, Zhang ZY, Vega-Montoto L, Vanacore RM, et al:
Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation
controls SMAD-dependent profibrotic signaling. J Clin Invest.
124:3295–3310. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar
|
|
38
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
